Conference Coverage

Universal BRCA testing worthwhile for relatives of high-grade serous ovarian cancer patients


 

REPORTING FROM ACOG 2018


“Any opportunity to prevent ovarian cancer is worthwhile,” Dr. Kwon commented. “If an ovarian cancer patient cannot be tested because she declines testing or, more commonly, because she is deceased, her first-degree relative should have BRCA mutation testing, regardless of other personal or family history or ethnicity.”

She and her coinvestigators reported no relevant financial disclosures.

Pages

Recommended Reading

Trastuzumab plus chemo shows efficacy for high HER2 endometrial cancer
MDedge ObGyn
VIDEO: Indocyanine green finds more sentinel lymph nodes
MDedge ObGyn
Disproportionately low U.S. research funding targets gynecologic cancers
MDedge ObGyn
What is HIPEC?
MDedge ObGyn
Two good apps for management of cervical cancer screening results
MDedge ObGyn
Oncofertility in women: Time for a national solution
MDedge ObGyn
How does oral contraceptive use affect one’s risk of ovarian, endometrial, breast, and colorectal cancers?
MDedge ObGyn
2018 Update on cervical disease
MDedge ObGyn
Leg lymphedema after gynecologic lymphadenectomy exceeds expectations
MDedge ObGyn
VIDEO: Office-based hereditary cancer risk testing is doable
MDedge ObGyn